KRT19 and hepatocellular carcinoma: As shown in Table 3, in stage I HCC, patients with CK19−/GPC3− expression took up the highest percentage (49.06%), then CK19−/GPC3+(41.07%) and CK19+/GPC3+(17.39%) (0.01<P<0.05).